Impact of Elexacaftor-Tezacaftor-Ivacaftor on fungal colonisation in children and adolescents with cystic fibrosis
Journal of Cystic Fibrosis · 2026-07 · 25 (4) · 643-650
DOI: 10.1016/j.jcf.2026.02.012 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Cystic Fibrosis, 2026-07. Verfasst von Emilie Sitterlé und 17 weiteren Autor:innen. Beteiligte Einrichtung: Unité de Parasitologie-Mycologie, Service de Microbiologie clinique, CHU Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), Pa…. Hauptthemen laut MEDLINE: Aminophenols, Benzodioxoles, Cystic Fibrosis, Indoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Association Vaincre la Mucoviscidose.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
BACKGROUND: CFTR modulators, such as elexacaftor/tezacaftor/ivacaftor (ETI), have markedly improved lung function in children with cystic fibrosis (cwCF). Their impact on fungal colonisation remains poorly investigated. METHODS: We conducted an ancillary prospective study within the real-world observational study MODUL-CF of cwCF naïve to CFTR modulators and initiating ETI. Clinical and microbiological data were collected up to 12 months before (baseline) and at 1, 3, 6, and 12 months post-ETI. Fungal colonisation, particularly Aspergillus, and its clinical impact were compared between Aspergillus-colonised and non-colonised children. RESULTS: A total of 238 cwCF from 26 centres were included. Fungal colonisation decreased from 59.2% to 47.0% (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unité de Parasitologie-Mycologie, Service de Microbiologie clinique, CHU Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.
- Centre de Référence Maladies Rares, Mucoviscidose et Maladies Apparentées, CHU Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), Centre Paris Cité, Paris, France.
- Chronic Childhood Diseases Unit, Pediatric Department, Nantes University Hospital, Nantes, France.
- Service de Médecin infantile, Centre de Ressources et de Compétences de la mucoviscidose pédiatrique, Hôpital d'enfants, CHRU de Nancy, Vandœuvre-lès-Nancy, France.
- Cystic Fibrosis Center. Centre Hospitalier Universitaire. Rennes, France.
- Hôpital Jeanne de Flandre - CHU de Lille, Centre de Ressources et de Compétence de la Mucoviscidose Pédiatrique, Lilles, France.
Förderung
- Association Vaincre la Mucoviscidose
Zitieren
APA
Sitterlé, E., Bonnel, A. S., Roussey-Bihouee, T., Blondé, A., Ribault, M., Wizla, N., Bresson, C., Persat, F., Maubon, D., Leroy, J., Hassani, F., Benhala, L., Mounier, M., Znaidi, S., Ferroni, A., Bougnoux, M. E., Sermet-Gaudelus, I., & Mycologist and Modul-CF groups (2026). Impact of Elexacaftor-Tezacaftor-Ivacaftor on fungal colonisation in children and adolescents with cystic fibrosis. Journal of Cystic Fibrosis, 25(4), 643-650. https://doi.org/10.1016/j.jcf.2026.02.012
Vancouver
Sitterlé E, Bonnel AS, Roussey-Bihouee T, Blondé A, Ribault M, Wizla N, et al. Impact of Elexacaftor-Tezacaftor-Ivacaftor on fungal colonisation in children and adolescents with cystic fibrosis. Journal of Cystic Fibrosis. 2026;25(4):643-650. doi:10.1016/j.jcf.2026.02.012
BibTeX
@article{Sitterl2026,
author = {Sitterlé, Emilie and Bonnel, Anne-Sophie and Roussey-Bihouee, Tiphaine and Blondé, Aurore and Ribault, Mélanie and Wizla, Nathalie and Bresson, Claire and Persat, Florence and Maubon, Danielle and Leroy, Jordan and Hassani, Fathia and Benhala, Lilia and Mounier, Morgane and Znaidi, Sadri and Ferroni, Agnès and Bougnoux, Marie-Elisabeth and Sermet-Gaudelus, Isabelle and Mycologist and Modul-CF groups, Mycologist and Modul-CF groups},
title = {Impact of Elexacaftor-Tezacaftor-Ivacaftor on fungal colonisation in children and adolescents with cystic fibrosis},
journal = {Journal of Cystic Fibrosis},
year = {2026},
volume = {25},
number = {4},
pages = {643--650},
doi = {10.1016/j.jcf.2026.02.012}
}
EUVIMED